MGX
Metagenomi, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$51.16M
P/E Ratio
—
EPS
$-2.36
Beta
0.57
52W High
$3.95
52W Low
$1.25
50-Day MA
$1.50
200-Day MA
$1.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Metagenomi, Inc. Common Stock
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
Fundamentals
| Revenue (TTM) | $25.21M |
| Gross Profit (TTM) | $-69.22M |
| EBITDA | $-90.70M |
| Operating Margin | -623.00% |
| Return on Equity | -44.70% |
| Return on Assets | -22.00% |
| Revenue/Share (TTM) | $0.68 |
| Book Value | $4.22 |
| Price-to-Book | 0.32 |
| Price-to-Sales (TTM) | 2.03 |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -59.30% |
| Shares Outstanding | $37.62M |
| Float | $27.32M |
| % Insiders | 27.74% |
| % Institutions | 20.14% |
Analyst Ratings
Consensus ($9.33 target)
4
Buy1
HoldData last updated: 4/8/2026